QUOTE AND NEWS
Business Wire  May 22  Comment 
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the following investor conferences:
StreetInsider.com  May 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/BioCryst+Pharma+%28BCRX%29+Posts+Narrower+than+Expected+Q1+Loss+of+13cShare%3B+Reaffirms/7406936.html for the full story.
Business Wire  May 7  Comment 
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2012. “We just completed our end of Phase 2 meeting with the FDA regarding our gout program. The agency provided clear and
Business Wire  May 1  Comment 
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the following investor conferences: 11th
Business Wire  Apr 25  Comment 
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2012 financial results will be released on Monday, May 7, 2012. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial
Benzinga  Mar 26  Comment 
Whole Foods Market Inc (NASDAQ: WFM) dipped 10.37% to $74.80 in the pre-market session. WFM's trailing-twelve-month profit margin is 3.55%. Cal-Maine Foods Inc (NASDAQ: CALM) moved down 2.50% to $40.90 in the pre-market session. Cal-Maine...
StreetInsider.com  Mar 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+%28BCRX%29+Seeks+to+Correct+Erroneous+Patent+on+HCV+Inhibitor/7263176.html for the full story.
TheStreet.com  Feb 17  Comment 
BOSTON (TheStreet) -- @WilliamPShelley kicks off this week's Biotech Stock Mailbag, asking "What are you thinking about Vivus' panel?" My predictions for next week's two very important FDA advisory panels: Vivus: Positive vote! Panel...
Benzinga  Feb 15  Comment 
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced favorable preclinical results for BCX5191, a novel adenine nucleoside analog targeting viral RNA polymerase for the potential treatment of hepatitis C. BioCryst has successfully...
StreetInsider.com  Feb 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+%28BCRX%29+Reports+Encouraging+Data+from+BCX5191+in+HCV/7181986.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki